Citi analyst Joel Beatty defended Sarepta Therapeutics (NASDAQ: SRPT) as "one of his Top Buys" ahead of ahead of LGMD ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE